Detalhe da pesquisa
1.
Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor.
Int J Mol Sci
; 25(1)2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38203787
2.
The JMJD6/HURP axis promotes cell migration via NF-κB-dependent centrosome repositioning and Cdc42-mediated Golgi repositioning.
J Cell Physiol
; 237(12): 4517-4530, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36250981
3.
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Anticancer Drugs
; 33(10): e842-e849, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36206101
4.
Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma.
Medicina (Kaunas)
; 58(7)2022 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35888627
5.
Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.
Oncology
; 99(1): 32-40, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32894845
6.
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Anticancer Drugs
; 32(10): 1099-1104, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34232936
7.
Impact of tumor disappearance ratio on the prognosis of lung adenocarcinoma ≤2 cm in size: A retrospective cohort study.
J Formos Med Assoc
; 120(2): 874-882, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32891489
8.
EGFR mutation and lobar location of lung adenocarcinoma.
Carcinogenesis
; 37(2): 157-162, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26645716
9.
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib.
Ther Adv Med Oncol
; 16: 17588359231220606, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38188463
10.
The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib.
Onco Targets Ther
; 16: 317-326, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37220494
11.
Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy.
Cancer Manag Res
; 15: 1251-1262, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37953889
12.
T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study).
Am J Cancer Res
; 13(7): 3100-3112, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37559987
13.
Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma.
Front Oncol
; 13: 1096683, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36925928
14.
Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer.
J Thorac Oncol
; 18(11): 1492-1503, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414358
15.
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients.
Sci Rep
; 12(1): 9753, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35697720
16.
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
Target Oncol
; 17(3): 295-306, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35460474
17.
Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid.
Cancers (Basel)
; 14(12)2022 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35740489
18.
Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).
Medicine (Baltimore)
; 101(24): e29381, 2022 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35713442
19.
Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018.
JAMA Netw Open
; 5(3): e224830, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35353165
20.
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Cancer Res Treat
; 54(2): 434-444, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34352999